// App-Quantinova.ai

3316 : Romiplostim for the Treatment of Adults with Primary Immune Thrombocytopenia (ITP) in Routine Clinical Practice Interim Results From a Large, European, Observational Study

Researchers

Presenter

  • Dominik Selleslag

Principal Investigators

  • Ann Janssens

  • Hans Wadenvik

  • Michael Steurer

  • Philippe Quittet

  • Georgia Kaiafa

  • Tomas Kozak

  • Helen Papadaki

  • Jean-François Viallard

  • Kerry Dillingham

  • Georg Kreuzbauer

Medical Centers

  • Department of Hematology, University Hospital Leuven, Leuven, Belgium

  • Department of Medical Oncology, Hopital Saint Eloi, Montpelier, France

  • Medical Propedeutic Department of Internal Medicine, AHEPA General Hospital, Thessaloniki, Greece

  • Department of Biochemistry, University of Crete, School of Medicine, Heraklion, Greece.

  • Department of Hematology, AZ Sint-Jan AV, Brugge, Belgium

  • Department of Haematology, Fakultni nemocnice Kralovske Vinohrady, Prague, Czech Republic,

  • Internal medicine department, Hopital du Haut Leveque - University of Bordeaux, Pessac, France

  • Hematology department, Sahlgrenska University hospital, Goteborg, Sweden

  • Division of Hematology and Oncology, Innsbruck Medical University, Innsbruck, Austria

Locations

  • Czech Republic

  • Greece

  • Austria

  • France

  • Belgium

  • Sweden

Companies

  • Amgen Inc.

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

  • Blood/haematological Diseases

  • Pulmonary/Respiratory Diseases

Disease

  • Immune thrombocytopenia

  • Deep vein thrombosis

  • Pulmonary embolism

  • Thrombocytopenia

  • Myelofibrosis

  • Venous thrombosis

Biomarkers

  • Aldo-Keto Reductase Family 1 Member B

  • Cluster of differentiation 95

  • Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Epsilon

Drug/Treatment

  • Romiplostim

  • Hemostatic Solution

Outcome

  • N/A

Study Design

  • observational

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved